Effect of long term CPAP therapy on cardiac parameters assessed with cardiac MRI

W. Wuest1 · M. S. May1 · M. Wiesmueller1 · M. Uder1 · A. Schmid1

Received: 22 June 2020 / Accepted: 9 September 2020 / Published online: 14 September 2020
© The Author(s) 2020, corrected publication 2021

Abstract
The obstructive sleep apnoea syndrome (OSAS) is a disorder with a high prevalence and is associated with an elevated cardiovascular risk and increased morbidity and mortality. For longitudinal studies and functional analysis cardiac MRI is regarded as the gold standard. Aim of this study was to evaluate the long-term effect of continuous positive airway pressure (CPAP) therapy on cardiac functional parameters with cardiac Magnetic Resonance Imaging (cMRI). 54 patients with OSAS (mean apnea hypopnea index-AHI: 31) were prospectively enrolled in this study and cMRI was performed before and after 7 months of CPAP therapy. Data were acquired on a 1.5 T MRI and right and left ventricular cardiac function were analysed. CPAP treatment was considered compliant when used ≥ 4 h per night. 24-h blood pressure was measured at baseline and follow up. 33 patients could be assigned to the compliance group. Left ventricular stroke volume (LV SV) and right ventricular ejection fraction (RV EF) improved significantly with CPAP therapy (LV SV from 93 ± 19 to 99 ± 20 ml, p = 0.02; RV EF from 50 ± 6 to 52 ± 6%, p = 0.04). All other cardiac parameters did not change significantly while mean systolic and diastolic blood pressure improved significantly (p < 0.01). 21 patients were assigned to the non-compliance group and were considered as a control group. There were no relevant differences in cardiac parameters between baseline and follow up examination in these patients. CPAP therapy seems to improve LV SV, RV EF, systolic and diastolic blood pressure in OSAS patients, but reproducibility of our results need to be confirmed in a larger patient population.

Keywords Cardiac MRI · Sleep apnea · CPAP therapy · Follow up

Introduction
Obstructive sleep apnea syndrome (OSAS) is a common sleep-related breathing disorder associated with heart failure [1–3]. People with OSAS suffer from complete closure of the pharynx, gasping episodes, sleep fragmentation, and daytime sleepiness, which could lead to hypoxia of the heart, elevated intrathoracic pressure, increased left ventricular afterload, and acute hypertension provoked by bursts of sympathetic activity [4–8]. The prevalence of OSAS is estimated to be at least 4% in men and 2% in women [9]. The standard treatment is continuous positive airway pressure (CPAP), first described by Sullivan et al. [4] in 1981. CPAP has been demonstrated to improve daytime performance and reduce cardiovascular effects associated with OSAS [10, 11]. Cardiac morphology and function are affected by OSAS, yet the exact mechanisms are still not completely understood. Most studies assessing cardiac morphology and function in OSAS have been performed with echocardiography, mainly focusing on the left ventricle. The quantitative assessment of right ventricular size and function is however often difficult. Generally, cardiac magnetic resonance imaging (cMRI) is considered the gold standard for volumes, EF, and mass and is well suited for the determination of left ventricular (LV) and right ventricular (RV) parameters because of the 3-dimensional volume acquisition [12–14].

The purpose of this study was to investigate the long-term effects of CPAP therapy on cardiac morphology and function in OSAS using cMRI and the long-term effect on blood pressure.

* W. Wuest
wolfgang.wuest@uk-erlangen.de

1 Radiological Institute, Friedrich-Alexander-University-Erlangen-Nuremberg, Maximiliansplatz 1, 91054 Erlangen, Germany
Materials and methods

Patient population

54 (44 males, 10 females) patients were included in this prospective study. Patients with atrial fibrillation, moderate to severe valvular heart disease, known coronary artery disease (CAD), previous cardiac surgery or any contraindication to cMRI or CPAP were excluded from the study.

All study subjects underwent a complete medical work-up including medication, clinical chemistry and physical examination. Use of medication was assessed at baseline and at follow-up measurements. Before OSAS treatment diagnostic polysomnography was performed. In this setting, the degree of OSAS and the sleep disturbance was quantified. The apnea hypopnea index (AHI) was assessed. Sleep stages were scored according to the standard criteria of the American Academy of Sleep Medicine [15]. Obstructive apneas were defined as the absence of oronasal flow for at least 10 s. Hypopneas were defined as reduction in airflow to ≤ 50% of the preceding stable baseline for 10 s or longer together with a dip in oxygen saturation ≥ 4%. The mean number of apneas and hypopneas per hour of sleep was calculated as AHI.

Only in CPAP-naive patients newly diagnosed with OSAS based on the overnight polysomnographic (PSG) exam (AHI > 5/h) baseline cMRI and 24 h blood pressure monitoring was performed.

After baseline cMRI all patients initiated CPAP treatment with CPAP machines equipped with compliance monitors that measured CPAP use. The prescribed CPAP pressure was based on a titration study that eliminated respiratory events and improved oxyhemoglobin saturation during sleep. Adequate compliance to the prescribed pressure of CPAP was defined as more than 4 h of CPAP use per night on a routine basis [16, 17]. Patients with usage of CPAP therapy for less than 4 h were enrolled in the control group (non-compliance group). All patients were evaluated at baseline and after 7 months of CPAP therapy.

Written informed consent was obtained from all patients and the institutional review board approved the study.

Image analysis

CMRI analysis was an average of independent readings performed by two observers (W.W. and A.S.) with more than 10 and 20 years of experience in cMRI, respectively, who were blinded to patient and other imaging data. Only patients examined at baseline and after 7 months of CPAP therapy were included in the final analysis. All patients were examined with a 1.5 T scanner (Magnetom Espree Quantum, Siemens Healthineers, Erlangen, Germany) and a 4-channel phased array body coil in supine position. Short, long axis and axial imaging was performed during breath-hold employing segmented 2D spoiled GRE sequences (field of view 240 × 320 mm², matrix 126 × 256, repetition time 9.9 ms, echo time 4.8 ms, flip angle 30°, slice thickness 8 mm) with a temporal resolution of 45 ms per image phase.

Figures 1 and 2 show examples of representative short axis stack for left ventricular and axial stack for right ventricular evaluation. LV endo- and epicardial and RV endocardial borders of each section from the base to the apex were identified manually at end diastole and end systole because manual delineation has been demonstrated to be the most accurate method for cardiac function analysis with MR imaging [18]. LV global mass and LV functional parameters were analysed in the short axis and RV functional parameters in the axial slices by using dedicated software (ARGUS; Siemens Healthineers, Erlangen, Germany). The trabecular network and the papillary muscles were attributed to the blood volume. The interventricular septum was regarded as part of the left ventricle with epi- and endocardial marks set as close together as possible.

The following parameters were evaluated: ejection fraction (EF), enddiastolic volume (EDV), endsystolic volume (ESV), stroke volume (SV), and LV myocardial mass (MM).

Statistical analysis

The nonparametric Wilcoxon’s matched-pairs test was used to evaluate differences between baseline and follow-up examination results. To compare baseline values between the study and control group student’s t-test was used. A p-value of < 0.05 was considered statistical significant. All parameters are given as mean ± standard deviation. Statistical analysis was performed using the software package SPSS Statistics version 21 (SPSS Inc./IBM, Chicago, IL).

Results

54 patients underwent both baseline and follow-up cMRI and were included in the data analysis. 33 patients (7 females and 26 males, mean age: 51 ± 11) were assigned to the compliance group and 21 patients (3 females, 18 males, mean age: 57 ± 7) to the non-compliant (control) group.

See Tables 1, 2, and 3 for complete patient characteristics. Blood pressure (24 h), body mass index (BMI) and AHI

Compliant group

CPAP therapy was used 5.6 ± 1.2 h/night.
At baseline, the mean BMI was $33 \pm 7$ kg/m$^2$, at follow up $33 \pm 6$ kg/m$^2$. Baseline AHI was $34 \pm 24$ h, the minimum oxygen saturation was $72 \pm 10\%$.

24 h blood pressure monitoring results could be retrieved in 25/33 (76\%) patients.

At time of enrollment, the mean systolic and diastolic BP was $135 \pm 12$ mmHg and $83 \pm 9$ mmHg, respectively. At follow up the mean systolic and diastolic BP improved significantly ($126 \pm 10$ mmHg and $76 \pm 8$ mmHg, $p = 0.005$ and $p = 0.002$).

7/33 (21\%) patients were on antihypertensive drugs (1 × ACE-inhibitor, 1 × β-blocker). In 2/33 (6\%) patients antihypertensive medication was started during CPAP therapy.

Non compliant group

CPAP therapy was used $1.9 \pm 1.2$ h/night.

At baseline, the mean BMI was $31 \pm 5$ kg/m$^2$, at follow up $30 \pm 5$ kg/m$^2$. Baseline AHI was $27 \pm 19$ h, the minimum oxygen saturation was $75 \pm 10\%$.

24 h blood pressure monitoring results could be retrieved in 13/21 (62\%) patients.

At time of enrollment, the mean systolic and diastolic BP was $131 \pm 13$ mmHg and $83 \pm 10$ mmHg, respectively. At follow up the mean systolic and diastolic BP improved but only the diastolic pressure significantly ($126 \pm 14$ mmHg and $79 \pm 13$ mmHg, $p = 0.1$ and $p = 0.04$).

6/21 (28\%) patients were on antihypertensive drugs and antihypertensive medication was not changed during CPAP therapy.

Baseline AHI and blood pressure results did not differ significantly between the study and non compliant group.

**Fig. 1** Representative example of an axial stack used for evaluation of right ventricular parameters
Fig. 2  Representative example of a short axis stack used for evaluation of left ventricular parameters

| Table 1  Baseline characteristics of total population (n = 54) |
|---------------------------------|-----------------|------------------|
|                                | Study group     | Control group    |
| Female (n)                     | 7 [21%]         | 3 [14%]          |
| Age (years)                    | 51 ± 11         | 57 ± 7           |
| Body-mass-index (kg/m²)        | 33 ± 7          | 31 ± 5           |
| AHI (h)                        | 34 ± 24 [range 5–103] | 27 ± 19 [range 7–79] |
| Blood pressure (mmHg)          |                 |                  |
| Systolic                       | 135 ± 12        | 131 ± 13         |
| Diastolic                      | 83 ± 9          | 83 ± 10          |
| Hypertonus (> 140/90 mmHg)     | 9 [27%]         | 3 [14%]          |
| Asthma                         | 3               | 0                |
| Dyslipidemia                   | 1               | 1                |
| Mean score on EES              | 9 ± 4           | 11 ± 5           |
| Min. O₂ (%)                    | 72 ± 10         | 75 ± 11          |
Baseline cardiac parameters did not differ significantly between the study and control group. See Tables 4 and 5 for complete cMRI results. Image quality was diagnostic in all patients and the examination could be completed in all cases.

**Compliant group**

LV SV and RV EF improved significantly after CPAP therapy (93 ± 19 ml vs. 99 ± 20 ml—p = 0.02 and 50 ± 6% vs. 52 ± 6% at follow up—p = 0.04). All other LV and RV cardiac parameters did not change significantly. In 3/33 patients (9%) LV EF improved by 15% and in 1/33 patients (3%) RV EF increased by 15%.

**Non compliant group**

There was no significant difference between baseline and follow up examination in the control group.
Table 3 Complete patient characteristics of the control group (n = 21)

| ACE-inhibitor/AT1-BL | β-blocker | ASS | CA-antagonist (verap.-typ) | β2-mimetics or theophyllin | Statin | Change of medication | Height (cm) | Weight (kg) | BMI (baseline) | BMI (follow up) |
|----------------------|-----------|-----|---------------------------|----------------------------|--------|---------------------|------------|------------|----------------|----------------|
| 0                    | 0         | 0   | 0                         | 0                          | 0      | No                  | 170        | 108        | 37.5           | 38.1           |
| 0                    | 0         | 0   | 0                         | 0                          | 0      | No                  | 185        | 110        | 32.1           | 30.4           |
| 1                    | 0         | 0   | 0                         | 0                          | 0      | No                  | 176        | 89         | 28.8           | 27.5           |
| 0                    | 0         | 0   | 0                         | 0                          | 0      | No                  | 185        | 115        | 33.6           | 30.7           |
| 0                    | 0         | 0   | 0                         | 0                          | 0      | No                  | 172        | 107        | 36.2           | 35.9           |
| 0                    | 0         | 0   | 0                         | 0                          | 0      | No                  | 170        | 83         | 28.8           | 28.8           |
| 0                    | 0         | 0   | 0                         | 0                          | 0      | No                  | 172        | 60         | 20.3           | 20.3           |
| 0                    | 0         | 0   | 0                         | 0                          | 0      | No                  | 168        | 105        | 37.2           | 36.8           |
| 0                    | 0         | 0   | 0                         | 0                          | 0      | No                  | 172        | 103        | 34.9           | 34.9           |
| 0                    | 0         | 0   | 0                         | 0                          | 0      | No                  | 156        | 67         | 27.5           | 26.7           |
| 0                    | 0         | 0   | 0                         | 0                          | 0      | No                  | 177        | 115        | 36.7           | 36.7           |
| 0                    | 0         | 0   | 0                         | 0                          | 0      | No                  | 178        | 123        | 38.9           | 37.9           |
| 0                    | 0         | 0   | 0                         | 0                          | 0      | No                  | 168        | 76         | 26.9           | 26.5           |
| 0                    | 1         | 1   | 0                         | 0                          | 0      | No                  | 170        | 69         | 23.9           | 23.6           |
| 0                    | 0         | 0   | 0                         | 0                          | 0      | No                  | 185        | 128        | 37.4           | 38.0           |
| 0                    | 0         | 0   | 0                         | 0                          | 0      | No                  | 184        | 84         | 24.8           | 25.4           |
| 0                    | 0         | 0   | 0                         | 0                          | 0      | No                  | 170        | 65         | 22.5           | 22.5           |
| 0                    | 0         | 0   | 0                         | 0                          | 0      | No                  | 165        | 89         | 32.7           | 34.1           |
| 0                    | 0         | 0   | 0                         | 0                          | 0      | No                  | 180        | 91         | 28.0           | 28.0           |
| 0                    | 0         | 0   | 0                         | 0                          | 0      | No                  | 185        | 100        | 29.2           | 29.2           |
| 0                    | 0         | 0   | 0                         | 0                          | 0      | No                  | 184        | 94         | 27.8           | 27.5           |
Discussion

We investigated cardiac effects of CPAP-therapy on 54 patients with OSAS after 7 months of treatment. LV SV, RV EF and systolic as well as diastolic blood pressure improved significantly in the compliance group using CPAP masks at least 4 h per night.

In OSAS recurrent episodes of complete obstruction (apnea) or partial obstruction (hypopnea) of the upper airway lead to intermittent hypoxia during sleep. Sleep can be divided in different stages and heart rate and systemic blood pressure are reduced and reach its lowest levels during the early periods of slow-wave sleep [19, 20]. Reasons for lowering of the blood pressure are the recumbent resting situation and sleep itself [21]. The apnea ventilation consists of different phases with a rising heart rate in the immediate postapneic period [22] and the highest blood pressure within the first postapneic breath [23]. By lowering nocturnal hypoxemia CPAP therapy reduces the systemic blood pressure, decreases the nocturnal blood pressure surge and alleviates the prognosis [24, 25]. In our study CPAP therapy reduced systolic and diastolic blood pressure significantly which is well in line with previous results [26]. Interestingly, in the non-compliant group we found no effect of CPAP therapy (< 4 h per night) on cardiac parameters however the diastolic blood pressure decreased significantly. With no change of medication in this group, we can only speculate that usage of CPAP therapy for less than 4 h has a positive effect on blood pressure with the diastolic pressure being the first to improve.

Not only the systemic pressure alters during sleep but also there is evidence that pulmonary artery pressure also changes during the obstructive sleep apnea cycle [27]. The strength of RV contraction is affected by pulmonary arterial resistance and in OSAS repetitive nocturnal elevations in pulmonary artery pressure and increased sympathetic discharges during apneic episodes may lead to RV remodeling and intermittent RV pressure overload [28, 29]. Other reasons for RV dysfunction may be due to chronic impacts of intermittent nocturnal hypoxemia and hypercapnia, LV dysfunction and systemic hypertension. Several studies report a significant fall in pulmonary arterial hypertension after 3 to 6 months of CPAP therapy [30–32]. We could show a significant increase of the right ventricular ejection fraction with no change of the other right ventricular cardiac parameters.

Apart from our study there are only two other previous reports using cMRI to examine the longitudinal effect of CPAP on cardiac functional parameters in OSAS patients. In the first study, Magalang et al. [33] investigated the effect of CPAP therapy in 13 patients after 3 months of therapy. They found no significant changes in LV functional parameters however, a significant decrease of RV EDV/ESV volumes and a trend towards improved RV EF.

In the second published study by Colish et al. [34] 47 patients were examined with cMRI and echocardiography at baseline and after 12 months of CPAP therapy. They also reported a trend towards increased RV EF but additionally a significantly decreased LV mass.

Some of the previously published studies using echocardiography report a positive effect of CPAP therapy on LV

### Table 4 Left ventricular (LV) baseline and follow-up results in the study and control group

|                | Baseline compliant | Follow up compliant | p-values | Baseline Non-compliant | Follow up Non-compliant | p-values |
|----------------|--------------------|---------------------|----------|------------------------|-------------------------|----------|
| LV mass (g)    | 135 ± 28           | 137 ± 28            | 0.58     | 135 ± 28               | 137 ± 28                | 0.78     |
| dEDV (ml)      | 149 ± 29           | 154 ± 29            | 0.20     | 147 ± 41               | 149 ± 37               | 0.30     |
| ESV (ml)       | 55 ± 18            | 55 ± 18             | 0.95     | 55 ± 20                | 58 ± 20                | 0.29     |
| SV (ml)        | 93 ± 19            | 99 ± 20*            | 0.02*    | 92 ± 25                | 92 ± 24                | 0.93     |
| EF (%)         | 63 ± 8             | 64 ± 8              | 0.29     | 63 ± 7                 | 62 ± 8                 | 0.49     |

*Significant results are marked

### Table 5 Right ventricular (RV) baseline and follow-up results in the study and control group

|                | Baseline compliant | Follow up compliant | p-values | Baseline Non-compliant | Follow up Non-compliant | p-values |
|----------------|--------------------|---------------------|----------|------------------------|-------------------------|----------|
| EDV (ml)       | 186 ± 37           | 188 ± 37            | 0.80     | 178 ± 35               | 179 ± 36                | 0.82     |
| ESV (ml)       | 93 ± 26            | 92 ± 24             | 0.50     | 86 ± 16                | 86 ± 16                 | 0.51     |
| SV (ml)        | 92 ± 18            | 92 ± 24             | 0.18     | 93 ± 23                | 93 ± 23                 | 1        |
| EF (%)         | 50 ± 6             | 52 ± 6*             | 0.04*    | 52 ± 5                 | 51 ± 5                  | 0.44     |

*Significant results are marked
functional parameters associated with OSAS [35], some do not [36]. Bayram et al. [37] treated 20 patients for 6 months with CPAP-therapy and found no change in LV EF. In contrast, Butt et al. [38] report a significant change of LV EF and LV EDV using M-Mode with no difference in LV ESV after treating 37 patients for 6 months with CPAP-therapy. However, in the same study these results were not reproducible using 2D and 3D echocardiography with no difference in LV EF, LV EDV and ESV.

Echocardiography data on the RV is sparse and only some papers are available. Bayram et al. [37] for example included 20 patients with newly diagnosed OSAS in their study. They found RV systolic and diastolic dysfunction improvement 6 months after CPAP therapy assessed by tissue Doppler imaging (TDI).

One reason for discrepancy between the results of cMRI and echocardiography studies could be that MR imaging enables more accurate morphologic analyses than does echocardiography [39]. CMRI is the gold standard for the analysis of both LV and RV functional parameters [14]. This is especially important in patients suffering from OSAS, who are mainly obese, which represents a major limitation for echocardiography to acquire adequate images.

Limitations

Our study has several limitations. First, the number of patients included is rather small but within the range of previous reported studies. Second, not all 24-h blood pressure monitoring results could be retrieved (76% in the compliant and 62% in the non compliant group).

Third, there was a change of medication (1 × ACE-inhibitor, 1 × β-blocker) in 2 patients (study group) between baseline and follow up cMRI. However in 31/33 (94%) patients medication was not altered thus we believe our results are representative for the effect of CPAP therapy.

Fourth, due to the small but significant differences found between RV and LV functional parameters the clinical significance needs to be confirmed in a larger patient cohort.

Conclusion

Using CPAP therapy > 4 h/night seems to improve LV SV and RV EF as measured with cMRI. It also seems to lower diastolic blood pressure even when used for less than 4 h/night.

Author contributions Data post processing: W.W; A.S; statistical analysis: W.W; A.S; M.W; drafting/editing the manuscript: W.W; A.S; M.U; enrolling of patients: W.W; A.S; M.W; data analysis and interpretation: W.W; A.S; M.W.

Funding Open Access funding enabled and organized by Projekt DEAL.

Data availability Data is available.

Compliance with ethical standards

Conflict of interest All authors are on the Siemens speaker bureau.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Sin DD, Fitzgerald F, Parker JD (1999) Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure. Am J Respir Crit Care Med 160:1101–1106
2. Javaheri S, Parker TJ, Liming JD (1998) Sleep apnea in 81 ambulatory male patients with stable heart failure: types and their prevalences, consequences, and presentations. Circulation 97:2154–2159
3. Shahar E, Whitney CW, Redline S (2001) Sleep-disordered breathing and cardiovascular disease: cross sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 163:19–22
4. The report of an American Academy of Sleep Medicine Task Force (1999) Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. Sleep 22:667–689
5. Bradley TD, Floras JS (2003) Sleep apnea and heart failure part I: obstructive sleep apnea. Circulation 107:1671–1678
6. Leung RST, Bradley TD (2001) Sleep apnea and cardiovascular disease. Am J Respir Crit Care Med 164:2147–2165
7. Parker JD, Brooks D, Kozar LF et al (1999) Acute and chronic effects of airway obstruction on canine left ventricular performance. Am J Respir Crit Care Med 160:1888–1896
8. Tkacova R, Rankin F, Fitzgerald FS, Floras JS, Bradley TD (1998) Effects of continuous positive airway pressure on obstructive sleep apnea and left ventricular afterload in patients with heart failure. Circulation 98:2269–2275
9. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S (1993) The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 328:1230–1235
10. Sullivan CE, Isa F, Berthon-Jones M, Eves L (1981) Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the nares. Lancet 317:862–865
11. Giles TL, Lasserson TJ, Smith BH, White J, Wright J, Cates CJ (2006) Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858

Springer
12. Fujimoto S, Mizuno R, Nakagawa Y, Dohi K, Nakano H (1998) Estimation of the right ventricular volume and ejection fraction by thoracoscopic three-dimensional echocardiography: a validation study using magnetic resonance imaging. Int J Card Imaging 14:385–390
13. Katz J, Whang J, Boxt LM, Barst RJ (1993) Estimation of right ventricular mass in normal subjects and in patients with primary pulmonary hypertension by nuclear magnetic resonance imaging. J Am Coll Cardiol 21:1475–1481
14. Petersen SE, Hudsmith LE, Robson MD et al (2006) Sex-specific characteristics of cardiac function, geometry, and mass in young adult elite athletes. J Magn Reson Imaging 24:297–303
15. Iber C, Ancoli-Israel S, Chesson A, Quan S. for the American Academy of Sleep Medicine (2007) The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specification. 1st ed. American Academy of Sleep Medicine, Westchester
16. Grunstein RR (1995) Sleep-related breathing disorders. 5. Nasal continuous positive airway pressure treatment for obstructive sleep apnoea. Thorax 50:1106–1113
17. Weaver TE, Grunstein RR (2008) Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. Proc Am Thorac Soc 5:173–178
18. Barbier CE, Johansson L, Lind L, Ahlström H, Bjerner T (2007) The exactness of left ventricular segmentation in cine magnetic resonance imaging and its impact on systolic function values. Acta Radiol 48:285–291
19. Bristow JD, Honour AJ, Pickering TG, Sleight P (1969) Cardiovascular and respiratory changes during sleep in normal and hypertensive subjects. Cardiovasc Res 3(4):476–485
20. Khatri IM, Freis ED (1967) Hemodynamic changes during sleep. J Appl Physiol 22(5):867–873
21. Pickering GW, Sleight P, Smyth HS (1967) The relation of arterial pressure to sleep and arousal in man. J Physiol 191(2):76P–78P
22. Zwillich C, Devlin T, White D, Douglas N, Weil J, Martin R (1982) Bradycardia during sleep apnea. Characteristics and mechanism. J Clin Invest 69(6):1286–1292
23. Shepard JW Jr (1990) Cardiopulmonary consequences of obstructive sleep apnea. Mayo Clin Proc 65(9):1250–1259
24. Shirasaki O, Yamashita S, Kawara S, Tagami K, Ishikawa J, Shimada K, Kario K (2006) A new technique for detecting sleep apnea-related ‘midnight’ surge of blood pressure. Hypertens Res 29:695–702
25. Kario K (2009) Obstructive sleep apnea syndrome and hypertension: ambulatory blood pressure. Hypertens Res 32(6):428–432
26. Kaneko Y, Floras JS, Usui K et al (2003) Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med 348:1233–1241
27. Sforza E, Laks L, Grunstein RR, Krieger J, Sullivan CE (1998) Time course of pulmonary artery pressure during sleep in sleep apnoea syndrome: role of recurrent apnoeas. Eur Respir J 11(2):440–446
28. Guidry UC, Mendes LA, Evans JC et al (2001) Echocardiographic features of the right heart in sleep-disordered breathing: the Framingham Heart Study. Am J Respir Crit Care Med 164:933–938
29. Fishman AP (2001) On keeping an eye on the right ventricle in sleep apnea. Am J Respir Crit Care Med 164:913–914
30. Alchanatis M, Tourkohoriti G, Kakouros S, Kosmas E, Podaras S, Jordanoglou JB (2001) Daytime pulmonary hypertension in patients with obstructive sleep apnea: the effect of continuous positive airway pressure on pulmonary hemodynamics. Respirat 68(6):566–572
31. Arias MA, García-Río F, Alonso-Fernández A, Martínez I, Villamar J (2006) Pulmonary hypertension in obstructive sleep apnoea: effects of continuous positive airway pressure: a randomized, controlled cross-over study. Eur Heart J 27(9):1106–1113
32. Sajkov D, Wang T, Saunders NA, Bune AJ, Mcevoy RD (2002) Continuous positive airway pressure treatment improves pulmonary hemodynamics in patients with obstructive sleep apnea. Am J Respir Crit Care Med 165(2):152–158
33. Magalang UJ, Richards K, McCarthy B, Fathala A, Khan M, Paranandi N, Raman SV (2009) Continuous positive airway pressure therapy reduces right ventricular volume in patients with obstructive sleep apnea: a cardiovascular magnetic resonance study. J Clin Sleep Med 5(2):110–114
34. Colish J, Walker JR, Elmayergi N, Almutairi S, Alharbi F, Lytwyn M, Francis A, Bohonis S, Zeglinski M, Kirkpatrick IDC, Sharma S, Jassal DS (2012) Obstructive sleep apnea: effects of continuous positive airway pressure on cardiac remodeling as assessed by cardiac biomarkers, echocardiography, and cardiac MRI. Chest 14:674–681
35. Chan J, Sanderson J, Chan W, Lai C, Choy D, Ho A, Leung R (1997) Prevalence of sleep-disordered breathing in diastolic heart failure. Chest 111:1488–1493
36. Niroomand M, Kuperstein R, Sasson Z, Hanly PJ (2001) Impact of obstructive sleep apnea on left ventricular mass and diastolic function. Am J Respir Crit Care Med 163:1632–1636
37. Bayram NA, Ciftci B, Bayram H, Keles T, Durmaz T, Akcam M, Yeter E, Bozkurt E (2008) Effects of continuous positive airway pressure therapy on right ventricular function assessment by tissue Doppler imaging in patients with obstructive sleep apnea syndrome. Echocardiography 25:1071–1078
38. Butt M, Dwivedi G, Shantsila A, Khair OA, Lip GY (2012) Left ventricular systolic and diastolic function in obstructive sleep apnea: impact of continuous positive airway pressure therapy. Circ Heart Fail 5:226–233
39. Grothues F, Smith GC, Moon JC, Bellenger NG, Collins P, Klein HU, Pennell DJ (2002) Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 90(1):29–34

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.